仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Alemtuzumab （Anti-CD52） is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD.